Anebulo Pharmaceuticals, Inc. (ANEB) Stock Analysis & Investment Frameworks
Anebulo Pharmaceuticals, Inc. (ANEB) stock analysis on Invetso. Review Anebulo Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Anebulo Pharmaceuticals, Inc. Company Overview
- Exchange: Other OTC
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Anebulo Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $11.22M
- Revenue: $N/A
- ROE: -64.46%
- ROIC: -81.32%
- Dividend Yield: N/A
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Anebulo Pharmaceuticals, Inc. (ANEB) across the following frameworks:
- Anebulo Pharmaceuticals, Inc. 10Y Growth Potential
- Anebulo Pharmaceuticals, Inc. Scenario Analysis
- Anebulo Pharmaceuticals, Inc. Risks & Opportunities
- Anebulo Pharmaceuticals, Inc. Economic Moat
- Anebulo Pharmaceuticals, Inc. Business Model
- Anebulo Pharmaceuticals, Inc. Management
- Anebulo Pharmaceuticals, Inc. SWOT Analysis
- Anebulo Pharmaceuticals, Inc. Porter's 5 Forces
- Anebulo Pharmaceuticals, Inc. PESTLE Analysis
- Anebulo Pharmaceuticals, Inc. ESG Analysis